Navigation Links
Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel
Date:9/2/2014

MONROVIA, Calif., Sept. 2, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Debra Zack, M.D., Ph.D., vice president, clinical development and the appointment of Lloyd Rowland, senior vice president, chief compliance officer and general counsel.

"Debra's expertise in biologics clinical development and medical affairs will be of great value to Xencor as we anticipate advancing the clinical development of XmAb5871® and XmAb7195®, and as we progress to the clinic with our lead bispecific candidates," said Bassil Dahiyat Ph.D., president and CEO of Xencor. "And Lloyd brings a wealth of legal, compliance and governance experience working with public companies and is an important addition to the team in our current stage of rapid growth. Their collective experience addresses critical needs and will be of increasing importance as our clinical pipeline steadily grows."  

Dr. Zack joins Xencor with more than a decade of experience in drug development. Prior to joining Xencor, Dr. Zack was executive director, medical scientific leader at Novartis Institute for Biological Research where she provided guidance in translational medicine for early project teams in rheumatology and regenerative medicine.  Before that, she had a long career at Amgen in various pre-clinical, clinical development, and medical affairs roles, most recently as the executive director, global development lead for Enbrel and executive director, global product area lead for rheumatology and dermatology. She earned her bachelor's degree in math and chemistry from Texas Christian University and earned her medical and doctoral degrees from University of Texas Southwestern Medical and Graduate School.

Mr. Rowland has more than two decades of biotechnology and pharmaceutical industry legal counsel and transactional experience. Prior to joining Xencor, Mr. Rowland served at Amylin Pharmaceuticals for twelve years, most recently as vice president and chief compliance officer and formerly, as general counsel and secretary. Earlier in his career, he served as vice president, secretary and general counsel for Alliance Pharmaceutical Corp. Mr. Rowland earned his bachelor's degree in economics and political science from Southern Methodist University, and earned his juris doctor from Emory University School of Law.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Currently, seven candidates are in clinical development internally and with partners that have been engineered with Xencor's XmAb® technology. Xencor's internally-discovered programs include XmAb5871, in Phase 1b/2a clinical trials for the treatment of Rheumatoid arthritis and lupus, XmAb7195 in Phase 1 development for the treatment of asthma, and XmAb5574/MOR208 which has been licensed to Morphosys AG and is in Phase 2 clinical trials for the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Amgen, Merck, Janssen R&D LLC, Alexion and Boehringer Ingelheim.

For more information, please visit www.xencor.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the U.S. securities laws, including statements associated with Xencor's research and its expectations regarding  future therapeutic and commercial potential of Xencor's technologies, programs, drug candidates and intellectual property related to Xencor's XmAb technology.  Because such statements are subject to risks and uncertainties, including risks associated with the process of discovering, developing and commercializing drugs that are safe and effective, actual results and the timing of events may differ materially from those expressed or implied by such forward-looking statements.  These and other risks concerning Xencor's programs and technology are described in additional detail in Xencor's SEC filings.  These forward-looking statements speak as of the date on which they were made, are based upon Xencor's current expectations and involve assumptions that may never materialize or may prove to be incorrect.  Xencor disclaims any intention or obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Xencor, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Xencor Prices Initial Public Offering
2. Xencors XmAb5871 Enters Phase 2a Study for Autoimmune Disease
3. Lycera Appoints Harinder Singh, Ph.D., as Chair of Scientific Advisory Board
4. Thesan Pharmaceuticals Appoints Dr. Bhaskar Chaudhuri to the Board of Directors August 2014
5. CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board
6. Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors
7. AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer
8. Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs
9. DuPont Tate & Lyle Bio Products Appoints Lipscomb Chemical as Distributor for Zemea® USP
10. Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors
11. Spherix Appoints Richard Cohen as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Buffalo, New York (PRWEB) , ... February 11, ... ... and analytical instruments for more than 150 years, continues today to pursue the ... to its line of analytical instruments: the AR9 Refractometer and the AR5 Refractometer. ...
(Date:2/10/2016)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a ... Mitsui & Co. Ltd., its partner in the ... investing an additional CDN$25 million in the joint venture ... 30% to 40%.  Mitsui will also play a stronger ... Sarnia , providing dedicated resources alongside ...
(Date:2/10/2016)... , Feb. 10, 2016 NX Prenatal ... its proprietary NeXosome® technology for early warning of ... its most recent study by Dr. Thomas ... the Society for Maternal Fetal Medicine,s (SMFM) annual meeting ... 1-6 th , 2016.  The presentation reported initial ...
(Date:2/10/2016)... Feb. 10, 2016  IsoRay, Inc. (NYSE MKT: ISR), ... and medical radioisotope applications for the treatment of prostate, ... announced its financial results for the second quarter and ... 2015. --> --> ... of fiscal 2016, which ended December 31, 2015, a ...
Breaking Biology Technology:
(Date:2/9/2016)... (NASDAQ: AWRE ), a leading supplier of biometrics software and ... ended December 31, 2015.  --> ... million, an increase of 61% compared to $4.3 million in the ... 2015 was $2.6 million compared to $0.2 million in the fourth ... Higher revenue and operating income in the fourth quarter of ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... is apparently one of the most popular hubs ... Project, MetaHIT and other huge studies of human ... that past few years, the microbiome space has ... applied biomedical research. This report focuses on ...
(Date:2/3/2016)... 3, 2016 ... the "Emotion Detection and Recognition Market ... Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020" ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition ...
Breaking Biology News(10 mins):